Life Sciences Archive » November, 2006

Life Sciences - November, 2006

104 articles

• Appeals Court Lets Biotech Patent Suit Proceed
• Drug-Coated Stents Face Further Scrutiny
• Eli Lilly & Co. Sued By 105 Plaintiffs Over Zyprexa
• Trial Starts In Pfizer's Norvasc Patent Dispute
• Court Refuses To Toss Claims Against Medtronic
• Drinker Biddle Merger Promises New Bankruptcy Force
• Merck Downplayed Vioxx Risks, Doctor Testifies
• Patent Lawyers Sweat As Supreme Court Hears Teleflex
• FDA Fines Red Cross For Blood-Safety Violations
• Cytosol Accosts Chubb For Insurance Money
• Wyeth, Others Face New Hormone Replacement Suit
• Federal Circuit Denies Amgen's Rehearing Request
• ITC To Review Smallpox Vaccine Ruling
• Court Rejects J&J Bid For Injunction In Amgen Case
• Judge Rules Vioxx Claims Should Be Tried Separately
• Cancer Vaccine Co. Files For Chapter 7
• State Attorney General Probes Off-Label Actiq Use
• Court Snubs Last-Ditch Motion In Univasc Suit
• Federal Circuit Boosts Impax In Aventis Patent Suit
• Teva To Pay Up To $70M To Settle With Pfizer
• FDA May Speed Drug Ad Review For Fee
• Bush Nominee For Family Planning Continues To Rankle
• New Cyberonics Chairman Probed For Backdating
• Appeals Court Revives Patent Suit Over Spinal Screws
• Another Republican Vows To Block FDA Confirmation
• Law Firm Profile: Epstein, Becker & Green
• Catheter Maker Settles Antitrust Suit
• Drinker Biddle Merger Creates Strong Securities Practice
• Drinker Biddle, Gardner Carton To Merge
• Drinker Biddle Merger To Boost Antitrust Practice
• Novo Nordisk Sues USPTO Over AERx Applications
• Pfizer Hardens Stance Over Chinese Viagra
• Alcon Sues Apotex To Block Generic Eye Drug
• Biovail CEO Tries To Muscle Back Into Bankruptcy Case
• Pharmaceutical Giants Face Wage And Hour Claims
• Drinker Biddle To Gain Top Health Care Group In Merger
• Federal Circuit Upholds Patent Ruling In Diprivan Case
• New Rules Addressing Physician Payment And Outpatient Procedures On Public Display
• Interference Proceeding Ordered In DNA Tech Spat
• Sales Rep Challenges Eli Lilly For Unpaid Overtime
• FDA Eyes Sanofi Antibiotic Over Safety Concerns
• Immune Response Settles Shareholder Suits
• Dusa Sues Chemical Co. Over Skin Treatment Patents
• Monsanto Fires Back At Solutia Noteholders
• Holders Name 13 Private Equity Firms In Antitrust Suit
• Generics Maker Settles Imitrex Suit With Glaxo
• Jury Gives Merck Another Vioxx Win
• U.S. Appeals Court Upholds Generic Zocor's Exclusivity
• Warner Chilcott Calls Truce Over Birth Control Drug
• Data Exclusivity Rules Rile Canadian Generics Makers
• Medical Device Co. Pokes Bayer With Suit Over Lancets
• Omnicare Settles Fraud Charges For $49.5M
• Companies Settle Patent Suit Over Vascular Product
• Synergetics Starts A Battle In Eye Surgery Patent War
• Boeing Deal Stalled In Wake Of Milberg Weiss Scandal
• Stryker Wins Second Round In Bout With Acumed
• Shire Unit Asserts Adderall Patents Against Andrx
• SeraCare Agrees To Shareholder's Chapter 11 Plan
• Crowell Snags Health & Employment Boutique
• Vioxx Class Action Approved In Quebec
• Metabolife Forks Over $56M In Ephedra Settlement
• Court Scraps Counterclaims Against J&J Unit
• Spectrum Settles With Glaxo Over Imitrex
• FDA To Up Postmarket Regulation Of Medical Devices
• FTC Probes Adderall Settlement Between Barr, Shire
• Law Firm Profile: Robins, Kaplan, Miller & Ciresi LLP
• Democrats Take Control, Look To Reform Drug Laws
• Hypertension Patients Join Feud Over Pfizer's Norvasc
• Privilege Concerns Over Disclosures To Independent Auditors
• Shareholders Rebel Against Connetics
• Jury Rejects Doctor's Claim Over Genentech Drug
• Abbott's Ultane Patent Declared Invalid
• Advocates Can Subpoena White House In Plan B Suit
• Pharma Stalls U.S., Korean Free Trade Talks
• Generic Allegra To Remain On The Market
• Pfizer Attacked Over Lipitor Licensing Pact
• Bradley Pharmaceuticals Derivative Action Dismissed
• Stryker CEO Says DOJ Should End Price-Fixing Probe
• Merck Riled In Tax Dispute With U.S. And Canada
• Martha Stewart's Co. To Settle ImClone Suit For $30M
• Teva Motions Denied In Patent Spat With Pfizer
• High Court Ask DOJ To Weigh In On Damages
• QLT Liable For Unfair Trade In Visudyne Litigation
• Has the Federal Circuit Said Enough to Save Its "Motivation, Teaching, Suggestion" Test?
• Law Firm Profile: Bromberg & Sunstein LLP
• Apotex' Antitrust Claims In Patent Case Approved
• FDA Warns Bausch & Lomb After Plant Inspection
• Antitrust Suit Claims Eisai Duped Patent Agency
• Pharmaceutical Giants, Consumers Spar As Trial Looms
• Eli Lilly Receives Subpoena Over Zyprexa
• CV Therapeutics Offers $13.5M In Settlement Agreement
• Law Firm Profile: Dechert LLP
• Court Denies J&J Unit's Motion In Spinal Screw Suit
• Warner Chilcott Hit With Suit Over IPO Prospectus
• Israeli Researchers Want ImClone To Pay Royalties
• CVS-Caremark Merger Creates Antitrust Complications
• Ortho-McNeil Faces More Suits Over Contraceptive
• Cyberonics Shareholder Pushes For Annual Meeting
• Genentech Backtracks In Synagis Dispute
• As Prices Are Slashed, Drug Makers Eye German Law
• Judge Trebles Invitrogen's Cash Award
• Amerigroup To Fight Back Against $144M Verdict
• Glaxo Agrees To Settle Paxil Litigation For $63.8M
• Supreme Court Denies Ferring B.V.'s Petition